Welcome to our dedicated page for Monogram Orthopaedics SEC filings (Ticker: MGRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monogram Technologies Inc. (MGRM) SEC filings archive provides a detailed regulatory record of the company’s evolution from an emerging growth orthopedic robotics issuer to a wholly owned subsidiary of Zimmer Biomet. These documents include current reports on Form 8-K, delisting notices on Form 25 and other materials that describe both its technology milestones and its change in corporate control.
For investors analyzing Monogram’s historical operations, Form 8-K filings are particularly important. They document events such as FDA 510(k) clearance for the Monogram mBôs TKA System, regulatory approval from India’s Central Drugs Standard Control Organization to import the mBôs TKA system for a 102-patient multi-center clinical investigation, and announcements related to the world’s first fully autonomous saw-based robotic total knee arthroplasty surgery on a live patient using the mBôs TKA System. Other 8-Ks outline financing and capital structure developments, including the creation and terms of the company’s Series E Redeemable Perpetual Preferred Stock and the mandatory conversion of its 8.00% Series D Convertible Cumulative Preferred Stock.
The merger with Zimmer Biomet is extensively detailed in Monogram’s merger-related 8-Ks. These filings describe the Agreement and Plan of Merger, the per-share cash consideration and contingent value rights (CVRs) for common stockholders, treatment of preferred stock and stock options, and the specific product development, regulatory and revenue milestones associated with potential CVR payments. A later Form 8-K dated October 7, 2025, confirms completion of the merger, explains that Monogram became a wholly owned subsidiary of Zimmer Biomet, and outlines the resulting change of control and modifications to stockholder rights.
Delisting and deregistration steps are reflected in the Form 25 filed by Nasdaq Stock Market LLC on October 7, 2025, which formally notifies the SEC of the removal of Monogram’s common stock from listing and registration under Section 12(b) of the Exchange Act. The October 7, 2025 Form 8-K further notes that trading in Monogram’s common stock was halted on the merger closing date and that the company intended to file a Form 15 to terminate registration of the common stock and suspend its periodic reporting obligations.
On Stock Titan, Monogram’s SEC filings are updated in line with EDGAR and can be paired with AI-powered summaries to help readers interpret complex documents. Users can review historical 10-K and 10-Q filings (where available), current reports on Form 8-K describing material events, and transaction-related documents that explain the structure and implications of the Zimmer Biomet acquisition and the CVR framework. This archive serves as a reference for understanding Monogram’s regulatory history, technology milestones and the steps leading to the delisting of the MGRM ticker.
Monogram Technologies Inc. became a wholly owned subsidiary of Zimmer Biomet through a merger effective
Noel Knape, Chief Financial Officer, reported a Form 4 disclosing changes in ownership tied to a merger with Zimmer Biomet. At the merger each outstanding share converted into
Monogram Technologies completed its previously announced merger with Zimmer Biomet through Honey Badger Merger Sub, with Monogram surviving as a wholly owned subsidiary of Zimmer Biomet. The Merger was effected under an Agreement and Plan of Merger dated
Monogram Technologies Inc. filed a Form 25 notification indicating a class of its securities is being removed from listing and/or registration on the Nasdaq Stock Market LLC. The form lists the issuer's principal office in Austin, Texas, cites the Exchange Act withdrawal rules, and includes the standard Nasdaq certification that the Exchange has reasonable grounds to file the Form 25. The filing text does not provide an effective date, which specific rule box was checked, or a completed signature block in the provided content.
Monogram Technologies Inc. (MGRM) director Paul Riss reported a grant of 10,000 stock options on 01/08/2025. The options have an exercise price of $2.50 and are shown with an exercisable date of 01/08/2032 and an expiration date of 01/08/2035, covering 10,000 underlying shares. After the reported transaction the filing shows 40,000 shares beneficially owned by the reporting person in a direct form. The form notes the company uses the Black-Scholes-Merton model to value awards and includes the reporting person signature dated 09/30/2025.
Douglas Unis, a director of Monogram Technologies Inc. (MGRM), received a stock option award and reports his beneficial ownership. The Form 4 discloses a grant of a stock option on 01/08/2025 to purchase 35,000 shares of common stock with an exercise price of $2.50. The option becomes exercisable on 01/08/2032 and expires on 01/08/2035. After this transaction, the filing reports 1,475,000 shares beneficially owned by Mr. Unis held directly. The form includes a note that the company uses the Black-Scholes model to value stock awards.
Monogram Technologies insider option grant to CTO reported. The filing shows Kamran Shamaei, identified as Chief Technology Officer and a director/officer, was granted a stock option on 01/08/2025 to acquire 250,000 shares of common stock at an exercise price of $2.50 per share. The option becomes exercisable on 01/08/2032 and expires on 01/08/2035. The reported transaction increases direct beneficial ownership by 250,000 shares. The explanation notes the company uses the Black-Scholes model to value stock awards.
Noel Knape, Chief Financial Officer and Director of Monogram Technologies Inc. (MGRM), reported a transaction on Form 4 showing an award of derivative securities. The filing reports that on 01/08/2025 Mr. Knape was granted 40,000 stock options with an exercise price of $2.50. The options have a date exercisable of 01/08/2032 and an expiration date of 01/08/2035, and the underlying security is common stock. The Form identifies Mr. Knape’s address in Austin, TX and is signed by him on 09/30/2025. The filing includes an explanatory note that the company uses the Black-Scholes-Merton model to determine fair value of stock awards.
Monogram Technologies (MGRM) Form 3 initial ownership filing: Director Richard Lee Van Kirk Jr. reported an option to acquire 2,000 shares of common stock. The option is exercisable beginning 07/31/2027 and expires 07/31/2030. The filing was made as an initial statement by one reporting person and identifies Van Kirk as a director. No other securities or transactions are disclosed in this Form 3.
Monogram Technologies Inc. filed an update on its planned merger with Zimmer Biomet Holdings. Zimmer Biomet, as the acquiring party, voluntarily withdrew and, on the same day, resubmitted its pre-merger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act in consultation with Monogram. This refiling starts a new 30-day antitrust waiting period that runs until October 6, 2025, at 11:59 p.m. Eastern Time, unless it is terminated earlier or extended.
The companies describe this withdraw-and-refile step as a standard procedure to give the Federal Trade Commission more time to review the transaction. Monogram and Zimmer Biomet state they are working constructively with FTC staff and continue to expect the merger to close in the second half of 2025, subject to required regulatory approvals, approval of the merger agreement by Monogram shareholders, and other customary closing conditions.